Objective. The PMR activity score (PMR-AS) includes the CRP value, which may be lacking or invalid owing to anti-IL-6 therapy. Our objective was to develop alternatives to PMR-AS that do not require CRP.
Introduction
Disease activity in PMR can be assessed using a composite index of four clinical items (morning stiffness, elevation of the upper limbs, physician's global assessment and patient's pain) and CRP [1, 2] . A PMR activity score (PMR-AS) of <7 defines low disease activity and PMR-AS of >17 high disease activity [1, 2] . In everyday practice, a PMR-AS of >10 is the best cut-off [3] for defining a flare [4] and guiding adjustments in glucocorticoid dosage [5] . INSERM The acute-phase response as assessed by the ESR or CRP is often greatly increased in PMR and is both a sensitive indicator of disease activity independently from pain [2] and a predictor of relapse [6, 7] . However, CRP values are not always obtained during follow-up, and treatments such as IL-6 antagonists can normalize CRP levels [812] .
Three options are available for determining the PMR-AS when CRP is unavailable or uninterpretable. One is to use the ESR instead [1] ; however, strong IL-6 inhibition may also affect the ESR value. Another is to use the sum of the four clinical items of the PMR-AS (clin-PMR-AS), but a cut-off would have to be defined and the score validated. The third option is to replace the CRP by a value imputed based on the other score items (CRP-imp PMR-AS). An advantage of this last option is that the cut-offs defined for the PMR-AS would apply.
Our objectives were to build a CRP-imp PMR-AS and to evaluate how well clin-PMR-AS, CRP-imp PMR-AS and ESR-PMR-AS agreed with PMR-AS in an independent cohort of patients with or without tocilizumab therapy.
Methods

Patients
We used two independent cohorts of patients with PMR, the Club Rhumatisme et Inflammation (CRI) cohort [13] and the Tolerance and Efficacy of tocilizumab iN pOlymyalgia Rheumatica (TENOR) cohort (Clinicaltrials.gov, NCT01713842) [8] . The CRI cohort comprised 89 patients with PMR diagnosed by expert clinicians and a total of 137 visits. Some patients received glucocorticoid therapy. The TENOR cohort consisted of 20 patients with recent-onset PMR fulfilling Chuang criteria and naive to glucocorticoid therapy (supplementary Table S1 , available at Rheumatology online). They received three tocilizumab infusions, at weeks 0, 4 and 8, followed by prednisone from week 12 to 24. Visits occurred at baseline and at weeks 4, 8, 12, 16, 20 and 24 after initiation of tocilizumab. We have received ethics board approval from the Comité de Protection des Personnes Ouest 6, Brest, France (8 September 2011), and consent was obtained for each patient.
Evaluation of disease activity with and without CRP PMR-AS [2] was computed as the sum of morning stiffness (MST, in minutes), elevation of the upper limbs (EUL, rated 03), physician's global assessment on a 10-point visual analog scale (phVAS), pain intensity determined by the patient on a 10-point visual analog scale (pVAS) and CRP concentration (in milligrams per decilitre). ESR-PMR-AS [2] was computed in the same way, with ESR (in millimetres per hour Â 0.1) instead of CRP. Clin-PMR-AS was the sum of MST, EUL, phVAS and pVAS.
Statistical analysis
In the CRI cohort, we assessed correlations between PMR-AS items to determine which items would perform best for CRP imputation, and we computed PMR-AS and clin-PMR-AS. CRP-imp PMR-AS was built to obtain a new DAS, in order to correct the value of the clin-PMR-AS score, taking into account the absence of CRP. We first verified the high correlation between PMR-AS with and without CRP. Then we created a scatter plot, in which y represents PMR-AS and x clin-PMR-AS. We drew the trendline showing the relationship observed between PMR-AS and clin-PMR-AS. PMR-AS can be computed simply using a formula of linear regression, y = ax + b, in which CRP-imp PMR-AS = a(clin-PMR-AS) + b. In the TENOR cohort, we assessed agreement between CRP-imp PMR-AS and PMR-AS.
Differences between variables were assessed using the MannWhitney and 2 tests. Correlations were evaluated by Spearman's correlation coefficient. Agreement was analysed by computing Cohen's k. All statistical tests were performed with SPSS 23.0, 2012 (SPSS Inc., Chicago, IL, USA).
Results
Correlations between CRP and other items and between PMR-AS and clin-PMR-AS (CRI cohort)
As expected, CRP correlated well with each of the other four PMR-AS items (r = 0.380.60, P < 0.0001) and with clin-PMR-AS (r = 0.59, P < 0.0001). PMR-AS and clin-PMR-AS correlated closely with each other (r = 0.99, P < 0.0001; supplementary Table S2 , available at Rheumatology online). CRP correlated well with ESR (r = 0.66, P < 0.0001). Figure 1 shows a scatter plot, in which y represents PMR-AS and x clin-PMR-AS, illustrating the strong linear relationship between the two scores. Therefore, we performed a linear regression between PMR-AS and clin-PMR-AS to obtain the CRP-imp PMR-AS, which can be computed simply according to the formula: CRP-imp PMR-AS = 1.12(clin-PMR-AS) + 0.26.
Agreement between PMR-AS, clin-PMR-AS, CRP-imp PMR-AS and ESR-PMR-AS (CRI cohort)
Using cut-offs of 07, 7 to 410, 10 to 417 and 171, only 5 of 137 patients in the CRI cohort had discordant cut-offs for PMR-AS and CRP-imp PMR-AS values; the overall k value of 0.93 indicated near-perfect agreement (supplementary Table S3 , available at Rheumatology online). As anticipated, the clin-PMR-AS value was lower than the CRP-imp PMR-AS value. 
Agreement between PMR-AS, ESR-PMR-AS, clin-PMR-AS and CRP-imp PMR-AS (TENOR cohort)
CRP was imputed at visits 4, 8 and 12, because the three tocilizumab infusions were given at baseline and at weeks 4 and 8. Before tocilizumab therapy, all 20 patients had PMR-AS and CRP-imp PMR-AS values >17, whereas two patients had clin-PMR-AS values <17. At week 12, after two tocilizumab infusions, PMR-AS and clin-PMR-AS were concordant. At this time point, a single patient had a CRP-imp PMR-AS score >17. CRP-imp PMR-AS values were closely similar to PMR-AS values (Fig. 2) , whereas clin-PMR-AS values were lower in patients with active PMR. ESR-PMR-AS values were higher than PMR-AS values but did not respond to treatment within the first 2 weeks. During tocilizumab therapy, agreement was better between PMR-AS and clin-PMR-AS than between PMR-AS and CRP-imp PMR-AS (supplementary Table  S3 , available at Rheumatology online), and this is explained by the decrease of CRP during treatment.
Discussion
We evaluated options for assessing the activity of PMR when the CRP value was lacking or uninterpretable. These options were clin-PMR-AS, ESR-PMR-AS and CRP-imp PMR-AS.
The influence of CRP on PMR-AS has been studied previously. Leeb et al. [14] demonstrated that using all five items or using pVAS plus three of the other four items (CRP, MST, EUL and phVAS) did not alter the assessment of the treatment response, provided the response rate was <90%. The limited contribution of CRP to the PMR-AS value [2] is probably ascribable to the strong impact of pain in PMR. In our study, PMR-AS and clin-PMR-AS correlated closely with each other in populations with elevated or low CRP values. Nevertheless, clin-PMR-AS was generally lower than PMR-AS, particularly in patients with severe systemic inflammation. CRP imp PMR-AS might help both clinicians and researchers to correct the value of PMR-AS. Indeed, it is easy to calculate the CRP imp PMR-AS value for each patient using the formula CRP imp PMR-AS = 1.12 (clin-PMR-AS) + 0.26, and the clinician might use the regular value for remission or flare used with the original PMR-AS.
ESR Â 0.1 can be substituted for CRP to compute PMR-AS. The values are slightly higher but correlate well with PMR-AS [1] . However, tocilizumab also lowers the ESR. The cytokine IL-6 is a small secreted glycoprotein that activates cells via a heterodimeric signalling complex consisting of the IL-6 a-receptor (IL-6R), which is expressed only on hepatocytes and specific leucocyte subpopulations (classic signalling); and of the signaltransducing b-subunit glycoprotein 130 (gp130), of which several soluble forms exist in human blood and which are natural inhibitors of IL-6 trans-signalling. IL-6 has complex roles in controlling the inflammatory process. It acts on the hepatic acute-phase response and induces the secretion of CRP [11, 15] and other proteins.
This study supplies evidence that ESR-PMR-AS or CRP-imp PMR-AS is a valid alternative to PMR-AS for the everyday follow-up of patients without available CRP values and for those taking IL-6 antagonists. Nevertheless, using original PMR-AS (with CRP), the proportion of tocilizumab-treated patients who were misclassified for low vs high disease activity was very small.
